Ramucirumab, CAS 947687-13-0

Product Description: Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor[1][2].

Applications: Cancer-Kinase/protease

Formula: C6374H9864N1692O1996S46

References: [1]Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533./[2]Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53./[3]Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.

CAS Number: 947687-13-0

Molecular Weight: 143609.63

Compound Purity: 99.40

Research Area: Cancer

Solubility: H2O

Target: VEGFR

• Artikelnummer: MEXHY-P9920-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9920-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK